 NAPLES, Fla., July 8, 2021 PRNewswire -- Enveric Biosciences NASDAQ: ENVB Enveric or the Company, a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that the Company has received approval from the Israeli Ministry of Health to begin the Phase 12 portion of its study of its lead asset, EV101, designed to investigate the safety and efficacy of synthetic cannabidiol CBD when administered alone or in combination with clomiphene, concurrently with temozolomide, to treat patients suffering from recurrent or progressive glioblastoma GBM. 